DIVA Laboratories Ltd - Asset Resilience Ratio
DIVA Laboratories Ltd (4153) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4153 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how DIVA Laboratories Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see DIVA Laboratories Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down DIVA Laboratories Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does DIVA Laboratories Ltd carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$70.00K | 0.01% |
| Total Liquid Assets | NT$70.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: DIVA Laboratories Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
DIVA Laboratories Ltd Industry Peers by Asset Resilience Ratio
Compare DIVA Laboratories Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for DIVA Laboratories Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for DIVA Laboratories Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | NT$70.00K ≈ $2.21K |
NT$1.35 Billion ≈ $42.65 Million |
-0.35pp |
| 2023-12-31 | 0.35% | NT$4.37 Million ≈ $137.62K |
NT$1.24 Billion ≈ $39.18 Million |
+0.35pp |
| 2022-12-31 | 0.00% | NT$7.00K ≈ $220.54 |
NT$1.25 Billion ≈ $39.44 Million |
-0.08pp |
| 2021-12-31 | 0.08% | NT$946.00K ≈ $29.80K |
NT$1.18 Billion ≈ $37.23 Million |
-0.41pp |
| 2020-12-31 | 0.49% | NT$5.42 Million ≈ $170.63K |
NT$1.11 Billion ≈ $35.07 Million |
-3.66pp |
| 2019-12-31 | 4.15% | NT$53.96 Million ≈ $1.70 Million |
NT$1.30 Billion ≈ $41.00 Million |
+4.04pp |
| 2018-12-31 | 0.11% | NT$1.42 Million ≈ $44.83K |
NT$1.32 Billion ≈ $41.68 Million |
-- |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is he… Read more